Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label Extension Study of WVE-210201 in Patients previously enrolled in WVE-DMDX51-001

Trial Profile

A Multicenter, Open-Label Extension Study of WVE-210201 in Patients previously enrolled in WVE-DMDX51-001

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs WVE 210201 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Sponsors WaVe life Sciences
  • Most Recent Events

    • 09 Nov 2018 According to a WaVe life Sciences media release, the company expects to present interim analysis of dystrophin expression in muscle biopsies from this trial in second half of 2019.
    • 24 Aug 2018 New trial record
    • 09 Aug 2018 Status changed to recruiting, according to a WaVe life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top